CD19 and B-cell chronic lymphocytic leukemia: Initial success using anti-CD19 or CD20 CAR-NK cells in vitro led to a phase I/II trial of eleven patients with R/R CLL and/or Richter’s transformation (n = 5) or NHL (n = 6) [177,178,179].